Back to results
US 9,541,555 B2Granted
Replication protein
AssigneeCizzle Biotech Limited
InventorDawn Coverley
Life of this patent
Estimating the term…
Abstract
This invention relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity. The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer.
Claims13
A method for determining whether a subject has cancer, the method comprising:
- a) providing a biological sample from the subject;
- b) contacting the biological sample with an antibody that specifically binds to a Ciz1 splice variant which lacks the sequence VEEELCKQ (SEQ ID NO:
- 3), thereby forming a Ciz1 splice variant-antibody complex;
- c) detecting the complexes and thereby measuring the protein expression level of the Ciz1 splice variant in the sample;
- and
- d) comparing the protein expression level of the Ciz1 splice variant in the sample with the protein expression level of the Ciz1 splice variant in a control sample, wherein an elevated protein expression level of the Ciz1 splice variant indicates an increased likelihood that the subject has cancer.
3 more elements
A method of detecting a Ciz1 splice variant in a subject, wherein the Ciz1 splice variant lacks the sequence VEEELCKQ (SEQ ID NO:
- 3), the method comprising:
- a) contacting a biological sample from the subject with an antibody against the Ciz1 splice variant;
- and
- b) detecting binding between the Ciz1 splice variant and the antibody, thereby detecting the Ciz1 splice variant.
1 more element
Dependencies are inferred from the claim text.